Molecular Characterization of Clinical Response and Relapse in Patients with IDH1m Newly Diagnosed AML Treated with IVO + AZA in the AGILE Study

Pau Montesinos, MD discusses key updates from the global phase 3 AGILE study, as presented at the 2022 American Society of Hematology Annual Meeting, and speaks to the clinical implications of these data.

Related Videos

View All

Related Content

Magrolimab Plus Rituximab/Chemo Elicits Deep Responses in Relapsed/Refractory DLBCL

January 28th 2023

Lunning Lends Insight on Pivotal Data From Pan Pacific Lymphoma 2022

November 10th 2022

FDA Awards Fast Track Designation to Tamibarotene for Increased-Risk MDS

January 26th 2023

Sauter and Hill Talk Through CAR T-Cell Sequencing and Access in Lymphomas

November 7th 2022

UK’s MHRA Approves Zanubrutinib for CLL and MZL

January 19th 2023

Ibrutinib/Prednisone Provides No CR/PR Benefit vs Placebo/Prednisone in cGVHD

January 18th 2023

Magrolimab Plus Rituximab/Chemo Elicits Deep Responses in Relapsed/Refractory DLBCL

January 28th 2023

Lunning Lends Insight on Pivotal Data From Pan Pacific Lymphoma 2022

November 10th 2022

FDA Awards Fast Track Designation to Tamibarotene for Increased-Risk MDS

January 26th 2023

Sauter and Hill Talk Through CAR T-Cell Sequencing and Access in Lymphomas

November 7th 2022

UK’s MHRA Approves Zanubrutinib for CLL and MZL

January 19th 2023

Ibrutinib/Prednisone Provides No CR/PR Benefit vs Placebo/Prednisone in cGVHD

January 18th 2023

Magrolimab Plus Rituximab/Chemo Elicits Deep Responses in Relapsed/Refractory DLBCL

January 28th 2023

Lunning Lends Insight on Pivotal Data From Pan Pacific Lymphoma 2022

November 10th 2022

FDA Awards Fast Track Designation to Tamibarotene for Increased-Risk MDS

January 26th 2023

Sauter and Hill Talk Through CAR T-Cell Sequencing and Access in Lymphomas

November 7th 2022

UK’s MHRA Approves Zanubrutinib for CLL and MZL

January 19th 2023

Ibrutinib/Prednisone Provides No CR/PR Benefit vs Placebo/Prednisone in cGVHD

January 18th 2023

Related Content

Magrolimab Plus Rituximab/Chemo Elicits Deep Responses in Relapsed/Refractory DLBCL

January 28th 2023

Articles

Lunning Lends Insight on Pivotal Data From Pan Pacific Lymphoma 2022

November 10th 2022

Podcasts

FDA Awards Fast Track Designation to Tamibarotene for Increased-Risk MDS

January 26th 2023

Articles

Sauter and Hill Talk Through CAR T-Cell Sequencing and Access in Lymphomas

November 7th 2022

Podcasts

UK’s MHRA Approves Zanubrutinib for CLL and MZL

January 19th 2023

Articles

Ibrutinib/Prednisone Provides No CR/PR Benefit vs Placebo/Prednisone in cGVHD

January 18th 2023

Articles